What causes immuno-oncology drug resistance? 2 research teams uncover clues

Checkpoint-inhibiting cancer drugs don’t work for as many as half of patients, even when they’re combined with other cancer treatments. Now, two separate research groups have uncovered contributors to immuno-oncology drug resistance, offering insight that could lead to new treatment strategies.